Ezaladcigene resoparvovec - Neurocrine Biosciences/Voyager Therapeutics
Alternative Names: AAV-AADC; AAV-hAADC; AAV-hAADC-2; AAV-hAADC-gene-therapy - Voyager Therapeutics; AAV2-hAADC; AAV2-hAADC - Voyager Therapeutics; Aromatic-L-amino-acid-decarboxylase-gene-therapy; AV 201; GZ 404477; NBIb-1817; VY AADC01; VY AADC02; VY-AADCLatest Information Update: 02 Oct 2021
At a glance
- Originator University of California at San Francisco
- Developer National Institutes of Health (USA); University of California at San Francisco; Voyager Therapeutics
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Aromatic-L-amino-acid decarboxylase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 10 Aug 2021 Voyager Therapeutics completes a phase I trial in Parkinson's disease in USA (NCT03065192)
- 10 May 2021 Ezaladcigene resoparvovec is available for licensing as of 10 May 2021. https://www.voyagertherapeutics.com/contact/
- 10 May 2021 Discontinued - Phase-I for Parkinson's disease (In children) in USA (Intrastriatal)